Core Viewpoint - Mandi International has submitted an application for a main board listing on the Hong Kong Stock Exchange, but faces significant operational challenges despite maintaining revenue and profit growth in recent years [1][16]. Group 1: Financial Performance - Mandi International's revenue and net profit have shown growth, with revenues projected at 9.8 billion, 12.3 billion, and 14.5 billion RMB for 2022, 2023, and 2024 respectively, reflecting year-on-year growth rates of 25.08% and 18.49% [4][21]. - In the first half of 2025, the company reported revenue of 7.43 billion RMB, a year-on-year increase of 20.2%, and a net profit of 1.7 billion RMB, up 64% [4][21]. Group 2: Product and Market Challenges - Over 90% of Mandi International's revenue is derived from the Mandi® product line, with the core product, Minoxidil solution, experiencing a sales decline of approximately 25.41% in the first half of 2025, generating around 3.58 billion RMB [5][20]. - The number of distributors has been decreasing annually, with counts of 173, 150, 132, and 106 for the years 2022, 2023, 2024, and the first half of 2025 respectively [8][23]. Group 3: Marketing and R&D Expenditure - The company has adopted a "heavy marketing, light R&D" approach, with marketing expenses reaching 3.75 billion RMB in the first half of 2025, resulting in a sales expense ratio of 50.4% [9][24]. - R&D spending has significantly decreased, with a 67.41% year-on-year drop to 0.195 billion RMB in the first half of 2025, raising concerns about the company's ability to innovate and expand into new areas [9][24]. Group 4: Dividend Policy and Financial Health - Mandi International declared a substantial dividend of 7.7 billion RMB in the first half of 2025, exceeding its net profit of 1.74 billion RMB for the same period, leading to a significant decline in net current assets [12][27]. - The company's liquidity has deteriorated sharply, with net current assets dropping from 5.95 billion RMB at the end of 2024 to just 0.04 billion RMB [13][29].

Company Overview - Company is a leading professional consumer healthcare platform in China, focusing on comprehensive and long-term skin health and weight management solutions, with its core brand "Mandi" dominating the minoxidil market in China, holding a market share of 70.6% in 2024 [1][2][14] - The company has a strong foundation in hair loss treatment and is actively expanding into broader skin health and weight management sectors [1][6] Shareholding Structure and Development History - The listing is a spin-off of high-quality assets within the Three Life Pharmaceutical system, ensuring a stable and strong shareholder background [2][24] - The company was established in 1997 and was the first in China to obtain approval for a 5% minoxidil solution in 2001, filling a market gap [2][24] - After being acquired by Three Life Pharmaceutical in 2015, the company entered a rapid growth phase, with Three Life remaining the controlling shareholder [2][24] Business Layout - The company has established a clear business matrix covering hair, skin, and weight management, with hair health being the cornerstone of its operations [6][26] - The hair health segment contributes the majority of revenue, while the company is also expanding into skin health with products like "Lai Zi" for atopic dermatitis and the acne treatment "Kela Tlong" [6][26] - In weight management, the company is preparing to launch the semaglutide injection, targeting a market projected to be worth hundreds of billions [6][26] Financial Analysis - The company has experienced rapid revenue growth, with revenue projected to increase from RMB 982 million in 2022 to RMB 1.455 billion in 2024, representing a CAGR of 21.7% [7][27] - The Mandi product line is the primary revenue driver, expected to generate RMB 1.327 billion in 2024, accounting for 92.1% of total revenue [7][27] - The company maintains strong profitability, with net profit expected to rise from RMB 202 million in 2022 to RMB 390 million in 2024, a CAGR of 38.9% [7][28] Industry Overview - The hair loss treatment market in China is substantial, with over 339 million individuals affected by hair loss, primarily androgenetic alopecia (AGA), which accounts for 90% of cases [9][30][31] - The market for hair health management is projected to grow from RMB 52.7 billion in 2024 to RMB 171.4 billion by 2035, with a CAGR of 11.3% [9][30] - Minoxidil is recognized as the gold standard for hair loss treatment, with its market share expected to increase from 80% to 82.2% between 2024 and 2035 [10][32] Acne Treatment Market - The acne treatment market is also significant, with over 121.2 million patients in China, expected to grow to 131.6 million by 2035 [15][36] - The market for acne treatment drugs is projected to increase from RMB 5 billion in 2024 to RMB 7.1 billion by 2035 [15][36] - The company has secured exclusive rights to the first topical androgen receptor inhibitor, Kela Tlong, which is expected to fill a gap in the market [15][38] Weight Management Market - The weight management market in China is poised for explosive growth, with the number of overweight and obese individuals projected to rise from 277.4 million in 2024 to 342.2 million by 2035 [17][39] - The market for weight loss drugs is expected to grow from RMB 2.3 billion in 2024 to RMB 80.4 billion by 2035, with a CAGR of 37.9% [17][39] - The company is advancing its semaglutide injection, which is expected to become one of the first domestically approved weight management products in China [17][42]